Substituted tetrahydroisoquinolines and related compounds are provided.
Such compounds are ligands that may be used to modulate C5a receptor activity in
vivo or in vitro, and are particularly useful in the treatment of conditions associated
with pathological C5a receptor activation in humans, domesticated companion animals
and livestock animals. Pharmaceutical compositions and methods for using them to
treat such disorders are provided, as are methods for using such ligands for receptor
localization studies:
##STR1##
